USES OF ET743 FOR TREATING CANCER

(19)

(11)

EP 1 176 964 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	10.10.2007 Bulletin 2007/41

(45)	Mention of the grant of the patent:
	06.09.2006 Bulletin 2006/36

(21)	Application number: 00927584.3

(22)	Date of filing: 15.05.2000

(51)

International Patent Classification (IPC):

A61K 31/495^(2006.01)

A61P 35/00^(2006.01)

(86)	International application number:
	PCT/GB2000/001857

(87)	International publication number:
	WO 2000/069441 (23.11.2000 Gazette 2000/47)

(54)	USES OF ET743 FOR TREATING CANCER VERWENDUNGEN VON ET743 ZUR BEHANDLUNG VON KREBS UTILISATION DU COMPOSE ET743 POUR LE TRAITEMENT DU CANCER

(84)	Designated Contracting States:
	AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
	Designated Extension States:
	AL LT LV MK RO SI

(30)

Priority:

13.05.1999 GB 9911183
14.05.1999 GB 9911346
05.08.1999 GB 9918534
15.11.1999 GB 9927005
16.11.1999 GB 9927106
29.03.2000 GB 0007637

(43)	Date of publication of application:
	06.02.2002 Bulletin 2002/06

(60)	Divisional application:
	06011784.3 / 1702618
	06014005.0 / 1716853

(73)	Proprietor: PHARMA MAR, S.A.
	28760 Tres Cantos, Madrid (ES)

(72)

Inventors:

CVITKOVIC, Esteban
F-94278 Le Kremlin-Bicêtre (FR)
Demetri, George Daniel, Dept. of Adult Oncology
Boston, MA 02115 (US)
GUZMAN, Cecilia, Pharma Mar, S.A.
Tres Cantos, E-28760 Madrid (ES)
JIMENO, José, Pharma Mar, S.A.
Tres Cantos, E-28760 Madrid (ES)
LOPEZ LAZARO, Luis, Pharma Mar, S.A.
Tres Cantos, E-28760 Madrid (ES)
MISSET, Jean Louis, Service d'Oncologie
F-94804 Villejuif Cedex (FR)
TWELVES, C., Uni. of Glasgow, CRC Beatson Lab.
Bearsden, Glasgow G61 1BD (GB)
VON HOFF, Daniel D., Arizona Cancer Center
Tuscon, A Z 85724-5024 (US)

(74)	Representative: Ruffles, Graham Keith et al
	Marks & Clerk, 66-68 Hills Road Cambridge, Cambridgeshire CB2 1LA Cambridge, Cambridgeshire CB2 1LA (GB)

(56)

References cited: :

WO-A-99/51238
US-A- 5 256 663

WO-A-99/58125
US-A- 5 478 932

IZBICKA: "In vitro antitumor actitivity of the novel marine agent, Ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients " ANNALS OF ONCOLOGY, vol. 9, no. 9, 1998, pages 981-987, XP000900662
" Ecteinascidin-743 " DRUGS OF THE FUTURE, vol. 22, no. 11, 1997, page 1279 XP002145352
GIAVAZZI: " Ecteinascidin-743, a New Marine Natural Product with Potent Antitumor Activity " CLINICAL CANCER RESEARCH, vol. 4, no. 8, 1998, pages 1977-1983, XP000930036

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).